1. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 17

    A clinical study investigating changes in exposure to cigarette smoke chemicals in U.K. smokers who switch to using a tobacco heating product for a five-day period

    McEWAN M.(1); EBAJEMITO J.K.(1); GALE N.(1); ELDRIDGE A.(1); CAMACHO O.M.(1); MURPHY J.(1); HARDIE G.(1); PROCTOR C.J.(1)
    (1) British American Tobacco (Investments) Limited, R&D, Southampton, U.K.; (2) Celerion Inc., Lincoln, NE, U.S.A.
    Smoking is a leading cause of numerous diseases, particularly lung cancer, chronic obstructive pulmonary disease and cardiovascular diseases. Consequently, there is a recognized need to provide smokers with alternative nicotine-delivery devices that...
  2. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 13 (also presented at TSRC 2018)

    Genotoxicity evaluation of tobacco and nicotine delivery products: Part 1. Mouse lymphoma assay

    LEVERETTE R.(1); THORNE D.(2); BREHENY D.(2); FOWLER K.(1); McENANEY S.(3); LLOYD M.(3); CLEMENTS J.(3); BOMBICK B.(1); GACA M.(2)
    (1) RAI Services Company, Scientific & Regulatory Affairs, Winston-Salem, NC, U.S.A.; (2) British American Tobacco (Investments) Ltd., Southampton, U.K.; (3) Covance Laboratories Ltd, Harrogate, North Yorkshire, U.K.
    In vitro studies have been widely used to support the toxicological evaluation of chemicals and complex mixtures including cigarette smoke. In this study a variety of test matrices from different tobacco and nicotine delivery products was assessed...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 14 (also presented at TSRC 2018)

    Genotoxicity evaluation of tobacco and nicotine delivery products: Part 2. In Vitro micronucleus assay

    LEVERETTE R.(1); THORNE D.(2); BREHENY D.(2); FOWLER K.(1); McENANEY S.(3); WHITWELL J.(3); CLEMENTS J.(3); BOMBICK B.(1); GACA M.(2)
    (1) RAI Services Company, Scientific & Regulatory Affairs, Winston-Salem, NC, U.S.A.; (2) British American Tobacco (Investments) Ltd., Southampton, U.K.; (3) Covance Laboratories Ltd, Harrogate, North Yorkshire, U.K.
    In vitro studies have been widely used to support toxicological evaluations of chemicals and complex mixtures including cigarette smoke. In this study a variety of test matrices from tobacco and nicotine delivery products were assessed against a 3R4F...
  4. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, STPOST 26

    A review of aerosol exposure systems relative to the analysis of cytotoxicity: a CORESTA In vitro Toxicity Testing Sub-Group perspective

    THORNE D.(1); WIECZOREK R.(2); FUKUSHIMA T.(3); SHIN H.J.(4); LEVERETTE R.(5); BALLANTYNE M.(6); LI X.(7); BOMBICK B.(5)
    (1) British American Tobacco, R&D Centre, Southampton, U.K.; (2) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (3) Japan Tobacco Inc., Scientific Product Assessment Centre, Yokohama, Kanagawa, Japan; (4) KT&G Corporation, Daejeon, South Korea; (5) RAI Services Company, Winston-Salem, NC, U.S.A.; (6) Covance Laboratories Ltd, Harrogate, U.K.; (7) Zhengzhou Tobacco Research Institute of CNTC, Zhengzhou, P.R. China
    Aerosol exposure systems offer researchers a variety of ways to customise the exposure set-up, modify experimental parameters and provide a novel and versatile platform for in vitro aerosol research. These systems produce an aerosol that more closely...
  5. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, STPOST 35

    Comparison of the carcinogenic potential of tobacco smoke and electronic-cigarette aerosol using the Bhas cell transformation assay

    BREHENY D.(1); OKE O.(1); PANT K.(2); BRUCE S.W.(2); LAFORCE M.K.(2); CELESTIN N.(2); GAÇA M.D.(1)
    (1) British American Tobacco, R&D Centre, Southampton, U.K.; (2) BioReliance, Sigma-Aldrich Corp., Rockville, MD, U.S.A.
    In vitro cell transformation assays (CTA) are used to assess the carcinogenic potential of chemicals and complex mixtures. They can detect non-genotoxic as well as genotoxic carcinogens. The Bhas 42 CTA has been developed with both initiation and...
  6. CORESTA Congress, Quebec, 2014, Smoke Science/Product Technology Groups, ST 09

    Impact of reducing the number of analysis replicates prescribed by the Canadian Tobacco Reporting Regulations on the level of information obtained from cigarette emission testing

    VOISINE R.(1); ERRINGTON G.(2); McADAM K.G.(2)
    (1) Imperial Tobacco Canada Ltd, Montréal, QC, Canada; (2) British American Tobacco, Group R&D, Southampton, U.K.
    Before the introduction of the Canadian Tobacco Reporting Regulations (TRR), the Regulator stated a need to obtain more information on tobacco product emissions to support, amongst other things, “better program design” and the “right to know”. The...
  7. CORESTA Congress, Quebec, 2014, Smoke Science/Product Technology Groups, ST 83

    Steady-state and transient effective density of cigarette smoke

    CABOT R.(1); JOHNSON T.J.(2); OLFERT J.S.(2); YURTERI C.Ü.(1); McAUGHEY J.(1)
    (1) British American Tobacco, Group R&D, Southampton, U.K.; (2) University of Alberta, Department of Mechanical Engineering, Edmonton, Canada
    Effective particle density is an important aerosol characteristic and relates a particle’s mobility diameter to its mass; an understanding of both properties is important to model impaction and settling losses, such as in human lung deposition. The...